THE NITRIC OXIDE-RELEASING DERIVATIVE OF FLURBIPROFEN HCT1026 DECREASES VULNERABILITY OF NIGROSTRIATAL DOPAMINERGIC NEURONS TO MPTP VIA A SWITCH OF GLIA PROINFLAMMATORY PHENOTYPE: IMPLICATIONS FOR TREATMENT OF PARKINSON’S DISEASE